Skyrizi induction, maintenance therapy improves patient-reported symptoms in CD

CHARLOTTE, N.C. — Patient-reported outcomes of abdominal pain and stool frequency improved with risankizumab induction, while maintenance therapy was effective for symptomatic remission and resolution in patients with Crohn’s disease.“Abdominal pain and increased stool frequency are two of the most burdensome symptoms of Crohn’s disease. For patients, fast resolution of symptoms is an important goal in therapy,” Ryan Ungaro, MD, MS, associate professor of medicine at the Icahn School of Medicine at Mount Sinai, said. “Risankizumab, an anti-IL-23 biologic,Read More